aldose reductase in 1

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase with an IC50 value of 28.9 pM, which can target the relaxin hormone signaling pathway in prostate cancer models.

ALR2-IN-1 is a potent and selective ALR2 inhibitor with an IC50 value of 1.42 μM. ALR2-IN-1 possesses both antiglycemic and antioxidant activities and can be used to study the complications of diabetes.

Esmolol is an ultra-short-acting, cardioselective β1-adrenergic receptor blocker. Esmolol exerts antiarrhythmic effects by regulating the NK1 receptor (neurokinin 1 receptor) signaling pathway and effectively improves myocardial dysfunction after cardiopulmonary resuscitation.Esmolol can positively promote diabetic wound healing by inhibiting aldose reductase activity, reducing advanced glycation end-product formation, and promoting fibroblast migration.Esmolol serves as an important tool drug for mechanistic studies on cardiovascular diseases such as arrhythmias and diabetic foot ulcers.

3-Isomangostin is a potent human aldose reductase inhibitor with an IC50 of 3.48 uM; it is also an acetylcholinesterase selective inhibitor. 3-Isomangostin has free radical scavenging activity; it shows antiplasmodial activity with IC50 values in the rang

Aldose reductase-IN-4 (compound IIc) is an inhibitor of aldose reductase with IC50 values of 11.70 μM for ALR1 and 0.98 μM for ALR2, respectively [1].

Aldose reductase-IN-6 is a potent AR inhibitor. It reduces sorbitol accumulation and oxidative stress by blocking the polyol pathway, used for diabetic complications such as retinopathy and neuropathy research.

ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) inhibitor (IC50: 3.26 μM) and aldose reductase (ALR2) inhibitor (IC50: 3.06 μM) with anticancer effects.

APPA, an aldose reductase inhibitor, demonstrates efficacy in preventing apoptosis and symptoms of Streptozotocin-induced diabetes in rats through inhibition of the polyol pathway. This compound shows promise for research into diabetic nephropathy (DN) [1].

PTP1B/AKR1B1-IN-1 is a dual inhibitor targeting protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM for PTP1B and 4.3 μM for AKR1B1. It also inhibits T-cell protein tyrosine phosphatase (TC-PTP) with an IC50 of 9 μM. This compound acts as an insulin-mimetic in murine myoblasts, reduces AKR1B1-mediated sorbitol accumulation, and aids in managing blood glucose levels and inhibiting type 2 diabetes mellitus (T2DM) development [1].